RNA biomarkers in hypertensive disorders of pregnancy: systematic review

Journal of Perinatal Medicine, 2025

Полный текст Открытый доступ: Gold Метаданные (CSL-JSON)
DOI 10.1515/jpm-2025-0143
Достоверность данных 70 средняя
Как считается эта оценка

Складывается из проверяемых признаков самой записи: есть ли у статьи DOI, сколько независимых источников подтвердили её данные, заполнены ли обязательные поля и насколько свежо последнее подтверждение. Снижают оценку расхождения между источниками и отсутствие идентификатора. Значение от 80 означает, что запись опубликована без дополнительной проверки; от 60 до 79 — что она опубликована с пониженной достоверностью и ручная проверка желательна. Запись, выверенную редактором вручную, пересчёт не опускает ниже 90. Это оценка наших данных о статье, а не оценка самой статьи.

Аннотация

OBJECTIVES: The purpose of the study is to explore the potential of novel genetic markers in predicting and diagnosing hypertensive conditions during pregnancy, focusing on their role in key pathological processes. The relevance of this study is determined by the necessity to improve methods for the early detection and effective management of pregnancy complications, particularly those associated with elevated blood pressure, which pose a threat to the health of both mother and foetus. METHODS: The research methodology involves a systematic analysis of scientific literature from the past five years, specifically from 2019 to 2024, emphasising the integration of data from various populations and research approaches within the field of molecular medicine. RESULTS: The main findings demonstrate that certain molecular markers reflecting gene activity exhibit high accuracy in predicting the risks of complications associated with hypertension of pregnancy. It is established that these markers can detect disturbances in the regulation of vascular tone, angiogenesis processes, and inflammatory responses long before the onset of clinical symptoms. This opens up opportunities for timely medical intervention and a personalised approach to pregnancy management. CONCLUSIONS: The results of the study confirm the potential of utilising genetic markers in clinical practice to improve pregnancy outcomes and reduce risks for both mother and child. The practical value lies in the possibility of developing new screening programmes and therapeutic strategies based on the individual characteristics of patients, contributing to more effective management of hypertensive disorders during pregnancy.